CS
BLACU

Clear Street’s Bellevue Life Sciences Acquisition Corp. Unit BLACU Stock Holding History

Clear Street’s Portfolio BLACU Stock Details BLACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,679
Closed -$55.6K – 668
2024
Q4 		$55.6K Buy
4,679
+500
+12% +$5.67K ﹤0.01% 162
2024
Q3 		$45.8K Buy
4,179
+467
+13% +$5.14K ﹤0.01% 213
2024
Q2 		$40.3K Sell
3,712
-48
-1% -$528 ﹤0.01% 261
2024
Q1 		$42.4K Buy
3,760
+3,660
+3,660% +$39.3K ﹤0.01% 212
2023
Q4 		$1.06K Sell
100
-5,901
-98% -$62.6K ﹤0.01% 608
2023
Q3 		$64.1K Buy
+6,001
New +$63.5K ﹤0.01% 237
2023
Q2 		– Sell
-14,922
Closed -$154K – 1385
2023
Q1 		$154K Buy
+14,922
New +$153K 0.01% 145

Clear Street's BLACU Position: Q1 2025 in Review

Clear Street sold out of Bellevue Life Sciences Acquisition Corp. Unit (BLACU) in Q1 2025, closing a stake of 4,679 shares — an estimated $55.6K sold.

Clear Street first reported a position in BLACU in Q1 2023 and held it in 7 quarters. The position peaked at $154K in Q1 2023. 0 funds tracked by Wall St. Rank hold BLACU as of Q1 2025.

  • Clear Street reported no remaining Bellevue Life Sciences Acquisition Corp. Unit position as of Q1 2025 after selling out during the quarter.
  • Clear Street sold 4,679 Bellevue Life Sciences Acquisition Corp. Unit shares in Q1 2025, an estimated $55.6K.
  • Clear Street first reported a position in Bellevue Life Sciences Acquisition Corp. Unit in Q1 2023 and held it in 7 quarters.
  • Clear Street's Bellevue Life Sciences Acquisition Corp. Unit position peaked at $154K in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Unit as of Q1 2025.

Based on Clear Street's 13F filing for Q1 2025, filed 15 May 2025.